-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Stoke Therapeutics, Raises Price Target to $40

Benzinga·08/04/2026 12:48:18
Listen to the news
Wedbush analyst Laura Chico maintains Stoke Therapeutics (NASDAQ:STOK) with a Outperform and raises the price target from $38 to $40.